Cancer immunotherapy – an overview.- Artificial Intelligence and Machine Learning Approaches in Designing Immunotherapy in Cancer.- Recent advancements in immunotherapy for the treatment of metastatic breast cancer.- Breast Cancer Immunotherapy: A Team Science Approach.- Colorectal Cancers and Immunotherapy.- IMMUNOTHERAPY IN GLIOBLASTOMA.- Immunotherapy in Head and Neck Cancer.- Novel Immune Modulatory Agents in the Treatment of Non-Small Cell Lung Cancer.- Immunotherapy in melanoma.- Role of Immunotherapy in Ovarian Cancer: Advances, Challenges, and Future Perspectives.- Pancreatic Cancer Immunotherapy: A Team-Based Approach.- Advancing Prostate Cancer Treatment: Innovations and Challenges in Immunotherapy.- Immunotherapy in renal cell carcinoma.- Phenotypic Plasticity, Non-genetic Mechanisms, and Immune Drug Resistance in Cancer.
Ravi Salgia, MD, PhD
Professor and Arthur & Rosalie Kaplan Chair in Medical Oncology
City of Hope National Medical Center
Duarte, California, USA
Ravi Salgia, MD, PhD, is Chair of Medical Oncology & Therapeutics Research at City of Hope National Medical Center, in Duarte, California. Dr. Salgia also holds the Arthur and Rosalie Kaplan Chair in Medical Oncology. Previously, Dr. Salgia was Professor of Medicine, Pathology and Dermatology, and the Director of the Thoracic Oncology Program, and Aerodigestive Tract Program Translational Research at the University of Chicago. His research interests focus on novel therapeutics against lung cancer. Dr. Salgia has been honored with numerous awards, including being named one of the Top Doctors in America and awarded the Sun Pharma Distinguished Scientist Award (Clinical Sciences). Prior to his tenure at University of Chicago School of Medicine, Dr. Salgia was faculty at the Dana-Farber Cancer Institute and Harvard Medical School. He earned his undergraduate summa cum laude in mathematics, biology, and chemistry, and then his MD and PhD degrees from Loyola University in Chicago, IL, where he also completed fellowships in neurochemistry and physiology. He continued his postgraduate training with an internship and residency in internal medicine at The Johns Hopkins University School of Medicine in Baltimore, MD, followed by a fellowship in medical oncology at Dana-Farber Cancer Institute in Boston, MA, during which time he also served as a clinical fellow at Harvard Medical School in Boston.
Prakash Kulkarni, Ph.D., is Research Professor and Director of Translational Research in the Department of Medical Oncology and has a courtesy appointment in the Department of Systems Biology at the City of Hope National Medical Centre in Duarte, California. After receiving his PhD in biochemistry from India, he did postdoctoral training in biochemistry at the Indian Institute of Science and in cell biology at the New York University School of Medicine. He was an Assistant Professor at Johns Hopkins University School of Medicine where he was named the Irene and Bernard L. Schwartz Scholar of the Patrick Walsh Fund. He then moved to the W. M. Keck Laboratory for Structural Biology, University of Maryland Institute for Bioscience and Biotechnology Research, as a Research Associate Professor. Prior to joining Johns Hopkins, Prof. Kulkarni held Staff Scientist positions in the Division of Chemistry & Chemical Engineering, the Division of Biology at Caltech, and in the Department of Genetics at Yale University School of Medicine. His research interests are interdisciplinary and are focused on understanding at a system level how conformational dynamics of intrinsically disordered proteins and noise contribute to phenotypic switching, especially in cancer and evolution. Prof. Kulkarni was a Visiting Professor in the Department of Mathematics, and the Department of Bioengineering at the Indian Institute of Science and is currently a Visiting Professor in the Division of Biology and Biological Engineering at Caltech. He is a Fellow of the Royal Society of Biology, UK, and inducted Member, Sigma Xi, The Scientific Research Honor Society.
